X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6386) 6386
Newspaper Article (959) 959
Publication (477) 477
Book Review (66) 66
Book Chapter (52) 52
Magazine Article (38) 38
Book / eBook (9) 9
Conference Proceeding (5) 5
Trade Publication Article (5) 5
Web Resource (2) 2
Data Set (1) 1
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5175) 5175
dyspnea (3899) 3899
male (3121) 3121
female (3023) 3023
index medicus (2487) 2487
middle aged (2299) 2299
dyspnea - etiology (2070) 2070
aged (1946) 1946
adult (1607) 1607
patients (1441) 1441
respiratory system (1166) 1166
dyspnea - drug therapy (1085) 1085
treatment outcome (1027) 1027
medicine, general & internal (767) 767
care and treatment (743) 743
drug dosages (684) 684
chronic obstructive pulmonary disease (683) 683
diagnosis (672) 672
clinical trials (671) 671
mortality (640) 640
quality of life (627) 627
respiration (607) 607
pneumonia (603) 603
heart failure (587) 587
pain (575) 575
oncology (573) 573
cardiac & cardiovascular systems (564) 564
drug therapy (536) 536
dyspnea - physiopathology (533) 533
aged, 80 and over (527) 527
diagnosis, differential (506) 506
research (497) 497
pulmonary disease, chronic obstructive - drug therapy (495) 495
obstructive pulmonary-disease (491) 491
copd (482) 482
risk factors (478) 478
edema (472) 472
lung diseases (470) 470
asthma (468) 468
management (442) 442
chemotherapy (437) 437
dyspnea - diagnosis (437) 437
cancer (425) 425
dyspnea - chemically induced (424) 424
pulmonary disease, chronic obstructive - physiopathology (415) 415
lung diseases, obstructive (414) 414
abridged index medicus (413) 413
severity of illness index (411) 411
studies (408) 408
double-blind method (400) 400
medicine (399) 399
disease (379) 379
diarrhea (369) 369
infections (366) 366
health aspects (362) 362
tomography, x-ray computed (361) 361
bronchodilator agents - therapeutic use (360) 360
cancer therapies (359) 359
adolescent (356) 356
hypertension (348) 348
respiratory function tests (348) 348
palliative care (345) 345
prognosis (341) 341
exercise (339) 339
hospitals (337) 337
analysis (336) 336
time factors (333) 333
therapy (326) 326
anemia (313) 313
respiratory tract diseases (312) 312
electrocardiography (309) 309
acute disease (302) 302
biopsy (301) 301
dyspnea - therapy (300) 300
administration, inhalation (298) 298
medical research (294) 294
case report (293) 293
metastasis (287) 287
pediatrics (286) 286
prospective studies (283) 283
laboratories (278) 278
lungs (278) 278
asthma - drug therapy (275) 275
retrospective studies (270) 270
echocardiography (267) 267
family medical history (265) 265
follow-up studies (265) 265
drug therapy, combination (264) 264
heart failure - drug therapy (264) 264
child (260) 260
pulmonary disease, chronic obstructive - complications (260) 260
fda approval (255) 255
constipation (254) 254
internal medicine (254) 254
cardiovascular disease (253) 253
complications and side effects (247) 247
heart (247) 247
case studies (245) 245
disease progression (242) 242
lung cancer (239) 239
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6765) 6765
German (221) 221
French (193) 193
Spanish (66) 66
Japanese (42) 42
Italian (32) 32
Russian (24) 24
Dutch (23) 23
Polish (19) 19
Chinese (12) 12
Romanian (11) 11
Danish (6) 6
Finnish (5) 5
Hebrew (5) 5
Portuguese (5) 5
Czech (4) 4
Hungarian (4) 4
Norwegian (2) 2
Serbian (2) 2
Swedish (2) 2
Bulgarian (1) 1
Icelandic (1) 1
Korean (1) 1
Lithuanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 18, pp. 1671 - 1680
The frequency of COPD exacerbations during treatment with a triple inhaler — delivering a long-acting beta-agonist (LABA), a long-acting muscarinic antagonist... 
MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | IMPACT | PARALLEL-GROUP | DOUBLE-BLIND | TIOTROPIUM | RANDOMIZED CONTROLLED-TRIAL | FLUTICASONE PROPIONATE/SALMETEROL | SALMETEROL | Glucocorticoids - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Benzyl Alcohols - administration & dosage | Hospitalization - statistics & numerical data | Male | Dyspnea - etiology | Quinuclidines - administration & dosage | Chlorobenzenes - administration & dosage | Adrenergic beta-Agonists - administration & dosage | Adult | Female | Bronchodilator Agents - adverse effects | Adrenergic beta-Agonists - adverse effects | Glucocorticoids - adverse effects | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Pulmonary Disease, Chronic Obstructive - complications | Muscarinic Antagonists - administration & dosage | Androstadienes - administration & dosage | Intention to Treat Analysis | Quality of Life | Dyspnea - drug therapy | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Treatment outcome | Lung diseases, Obstructive | Care and treatment | Usage | Analysis | Diagnosis | Inhalers | Pneumonia | Acetylcholine receptors (muscarinic) | Glucocorticoids | Lung diseases | Critical care | Fluticasone | Patients | Quality of life | Medicine | Hospitals | Obstructive lung disease | Population | Chronic obstructive pulmonary disease | Drug dosages | Life Sciences | Human health and pathology | Pulmonology and respiratory tract
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 6, pp. 520 - 529
Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer.... 
TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | TAMOXIFEN | PHASE-III | LETROZOLE | SUPERIOR | AROMATASE INHIBITORS | FIRST-LINE THERAPY | ANASTROZOLE | Recurrence | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | TOR Serine-Threonine Kinases - antagonists & inhibitors | Aromatase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Aged, 80 and over | Postmenopause | Adult | Female | Aromatase Inhibitors - therapeutic use | Everolimus | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Receptor, Epidermal Growth Factor - analysis | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drugs | Care and treatment | Usage | Hormone therapy | Patient outcomes | Drug utilization | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | TOR protein | Anastrozole | Endocrine therapy | Fatigue | Intracellular signalling | Rapamycin | Tamoxifen | Cancer therapies | Survival | Post-menopause | Fulvestrant | Signal transduction | Stomatitis | Hyperglycemia | Chemotherapy | Pneumonitis | Dyspnea | Aromatase | Antitumor activity | Respiration
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 4, pp. 330 - 340
Journal Article
Lancet, The, ISSN 0140-6736, 01/2013, Volume 381, Issue 9860, pp. 29 - 39
Journal Article
Endocrine-related Cancer, ISSN 1351-0088, 2015, Volume 22, Issue 6, pp. 877 - 887
Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies. The DECISION trial was a multicenter, randomized,... 
Adverse events | Targeted therapy | Tyrosine kinase inhibitor | Sorafenib | Differentiated thyroid cancer | targeted therapy | sorafenib | EFFICACY | GUIDELINES | TIME | adverse events | differentiated thyroid cancer | DECREASES | TRIAL | ONCOLOGY | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | tyrosine kinase inhibitor | RENAL-CELL | EXPOSURE | Adenoma, Oxyphilic - enzymology | Dyspnea - chemically induced | Thyroid Neoplasms - enzymology | Prevalence | Adenocarcinoma, Follicular - radiotherapy | Humans | Middle Aged | Drug Resistance, Neoplasm | Hypertension - drug therapy | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Protein Kinase Inhibitors - adverse effects | Weight Loss - drug effects | Incidence | Neoplasms, Second Primary - chemically induced | Adenocarcinoma, Follicular - drug therapy | Adenoma, Oxyphilic - drug therapy | Hypocalcemia - epidemiology | Niacinamide - adverse effects | Carcinoma, Papillary - drug therapy | Niacinamide - therapeutic use | Thyroid Neoplasms - radiotherapy | Adenocarcinoma, Follicular - enzymology | Neoplasms, Second Primary - epidemiology | Niacinamide - analogs & derivatives | Diarrhea - epidemiology | Diarrhea - chemically induced | Iodine Radioisotopes - therapeutic use | Hypocalcemia - chemically induced | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Female | Carcinoma, Papillary - enzymology | Hypertension - epidemiology | Adenoma, Oxyphilic - radiotherapy | Drug Eruptions - etiology | Phenylurea Compounds - therapeutic use | Dyspnea - epidemiology | Disease-Free Survival | Carcinoma, Papillary - radiotherapy | Fatigue - epidemiology | Thyroid Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Aged | Diarrhea - drug therapy | Drug Eruptions - epidemiology | Radiopharmaceuticals - therapeutic use | Index Medicus | Research
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1104 - 1115
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 22, pp. 2083 - 2092
Journal Article